Literature DB >> 11812154

Surface expression of an immunodominant malaria protein B cell epitope by yellow fever virus.

Myrna C Bonaldo1, Richard C Garratt, Philippe S Caufour, Marcos S Freire, Mauricio M Rodrigues, Ruth S Nussenzweig, Ricardo Galler.   

Abstract

The yellow fever 17D virus (YF17D) has several characteristics that are desirable for the development of new, live attenuated vaccines. We approached its development as a vector for heterologous antigens by studying the expression of a humoral epitope at the surface of the E protein based on the results of modelling its three-dimensional structure. This model indicated that the most promising insertion site is between beta-strands f and g, a site that is exposed at the external surface of the virus. The large deletion of six residues from the fg loop of the E protein from yellow fever virus, compared to tick-born encephalitis virus, leaves space at the dimer interface for a large insertion without creating steric hindrance. We have tested this hypothesis by inserting a model humoral epitope from the circumsporozoite protein of Plasmodium falciparum consisting of triple NANP repeats. Recombinant virus (17D/8) expressing this insertion flanked by two glycine residues at each end, is specifically neutralized by a monoclonal antibody to the model epitope. Furthermore, mouse antibodies raised to the recombinant virus recognize the parasite protein in an ELISA assay. Serial passage analysis confirmed the genetic stability of the insertion made in the viral genome and the resulting 17D/8 virus is significantly more attenuated in mouse neurovirulence tests than the 17DD vaccine. The fg loop belongs to the dimerization domain of the E protein and lies at the interface between monomers. This domain undergoes a low pH transition, which is related to the fusion of the viral envelope to the endosome membrane. It is conceivable that a slower rate of fusion, resulting from the insertion close to the dimer interface, may delay the onset of virus production and thereby lead to a milder infection of the host. This would account for the more attenuated phenotype of the recombinant virus in the mouse model and lower extent of replication in cultured cells. The vectorial capacity of the yellow fever virus is being further explored for the expression and presentation of other epitopes, including those mediating T-cell responses. Copyright 2002 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11812154     DOI: 10.1006/jmbi.2001.5258

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  25 in total

1.  Attenuation of recombinant yellow fever 17D viruses expressing foreign protein epitopes at the surface.

Authors:  Myrna C Bonaldo; Richard C Garratt; Renato S Marchevsky; Evandro S F Coutinho; Alfredo V Jabor; Luís F C Almeida; Anna M Y Yamamura; Adriana S Duarte; Prisciliana J Oliveira; Jackeline O P Lizeu; Luiz A B Camacho; Marcos S Freire; Ricardo Galler
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

2.  Characterization of a permissive epitope insertion site in adenovirus hexon.

Authors:  Michael J McConnell; Xavier Danthinne; Michael J Imperiale
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

3.  Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone.

Authors:  Xiaohong Jiang; Tim J Dalebout; Igor S Lukashevich; Peter J Bredenbeek; David Franco
Journal:  J Gen Virol       Date:  2014-12-16       Impact factor: 3.891

Review 4.  The yellow fever 17D virus as a platform for new live attenuated vaccines.

Authors:  Myrna C Bonaldo; Patrícia C Sequeira; Ricardo Galler
Journal:  Hum Vaccin Immunother       Date:  2014-02-19       Impact factor: 3.452

5.  Improved genetic stability of recombinant yellow fever 17D virus expressing a lentiviral Gag gene fragment.

Authors:  Marlon G Veloso de Santana; Patrícia C C Neves; Juliana Ribeiro dos Santos; Noemia S Lima; Alexandre A C dos Santos; David I Watkins; Ricardo Galler; Myrna C Bonaldo
Journal:  Virology       Date:  2014-02-08       Impact factor: 3.616

Review 6.  Production of recombinant proteins from protozoan parasites.

Authors:  José A Fernández-Robledo; Gerardo R Vasta
Journal:  Trends Parasitol       Date:  2010-02-26

7.  Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs.

Authors:  Xiaohong Jiang; Tim J Dalebout; Peter J Bredenbeek; Ricardo Carrion; Kathleen Brasky; Jean Patterson; Marco Goicochea; Joseph Bryant; Maria S Salvato; Igor S Lukashevich
Journal:  Vaccine       Date:  2010-12-08       Impact factor: 3.641

8.  The live-attenuated yellow fever vaccine 17D induces broad and potent T cell responses against several viral proteins in Indian rhesus macaques--implications for recombinant vaccine design.

Authors:  Philip A Mudd; Shari M Piaskowski; Patricia C Costa Neves; Richard Rudersdorf; Holly L Kolar; Christopher M Eernisse; Kim L Weisgrau; Marlon G Veloso de Santana; Nancy A Wilson; Myrna C Bonaldo; Ricardo Galler; Eva G Rakasz; David I Watkins
Journal:  Immunogenetics       Date:  2010-07-07       Impact factor: 2.846

9.  Recombinant yellow fever vaccine virus 17D expressing simian immunodeficiency virus SIVmac239 gag induces SIV-specific CD8+ T-cell responses in rhesus macaques.

Authors:  Myrna C Bonaldo; Mauricio A Martins; Richard Rudersdorf; Philip A Mudd; Jonah B Sacha; Shari M Piaskowski; Patrícia C Costa Neves; Marlon G Veloso de Santana; Lara Vojnov; Saverio Capuano; Eva G Rakasz; Nancy A Wilson; John Fulkerson; Jerald C Sadoff; David I Watkins; Ricardo Galler
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

10.  Engineering the Japanese encephalitis virus RNA genome for the expression of foreign genes of various sizes: implications for packaging capacity and RNA replication efficiency.

Authors:  Sang-Im Yun; Yu-Jeong Choi; Xiao-Fang Yu; Jae-Young Song; Young-Hak Shin; Young-Ran Ju; Seok-Yong Kim; Young-Min Lee
Journal:  J Neurovirol       Date:  2007-12       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.